References |
Top |
REF 1 |
Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 2007 Jun 1;67(11):5513-21.
|
REF 2 |
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res. 2005 Jan 7;33(1):13-26.
|
REF 3 |
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002 Jul 15;21(14):3715-27.
|
REF 4 |
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007 Nov 1;67(21):10455-65.
|
REF 5 |
Hispolon promotes MDM2 downregulation through chaperone-mediated autophagy. Biochem Biophys Res Commun. 2010 Jul 16;398(1):26-31.
|
REF 6 |
Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8247-52.
|
REF 7 |
A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2. Cell Signal. 2014 Jun;26(6):1243-57.
|
REF 8 |
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001 Nov;3(11):973-82.
|
REF 9 |
Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT. Oncogene. 2010 Jul 15;29(28):4101-12.
|
REF 10 |
The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007 Oct;12(4):342-54.
|
REF 11 |
A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene. 1998 Nov 19;17(20):2629-36.
|
REF 12 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
REF 13 |
Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle. 2009 Feb 1;8(3):430-7.
|
REF 14 |
14-3-3 Binding to Pim-phosphorylated Ser166 and Ser186 of human Mdm2--Potential interplay with the PKB/Akt pathway and p14(ARF). FEBS Lett. 2009 Feb 18;583(4):615-20.
|
REF 15 |
Coordinate regulation of estrogen receptor degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene. 2013 Jan 3;32(1):117-26.
|
REF 16 |
A comprehensive resource of interacting protein regions for refining human transcription factor networks. PLoS One. 2010 Feb 24;5(2):e9289.
|
REF 17 |
XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. EMBO J. 2013 Aug 14;32(16):2204-16.
|
REF 18 |
Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem. 2003 Apr 18;278(16):13595-8.
|
REF 19 |
Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol. 2011 Nov 30;9:83.
|
REF 20 |
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene. 2006 Nov 23;25(55):7274-88.
|
REF 21 |
Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell. 2009 Aug 14;35(3):316-26.
|
REF 22 |
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005 Nov 3;24(48):7238-47.
|
REF 23 |
An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis. J Proteome Res. 2012 Nov 2;11(11):5464-78.
|
REF 24 |
Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol. 2006 Sep;26(18):6819-31.
|
REF 25 |
OTUD5 regulates p53 stability by deubiquitinating p53. PLoS One. 2013 Oct 15;8(10):e77682.
|
REF 26 |
The ubiquitin ligase Mdm2 controls oligodendrocyte maturation by intertwining mTOR with G protein-coupled receptor kinase 2 in the regulation of GPR17 receptor desensitization. Glia. 2015 Dec;63(12):2327-39.
|
REF 27 |
MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem. 2002 Aug 23;277(34):30838-43.
|
REF 28 |
DNA damage-induced activation of ATM promotes -TRCP-mediated Mdm2 ubiquitination and destruction. Oncotarget. 2012 Sep;3(9):1026-35.
|
REF 29 |
Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. J Mol Biol. 2004 Mar 12;337(1):115-28.
|
REF 30 |
p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998 Oct;2(4):405-15.
|
REF 31 |
MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005 Sep 21;24(18):3279-90.
|
REF 32 |
Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. Mol Cell. 2016 Jun 16;62(6):890-902.
|
REF 33 |
Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem. 2003 Mar 28;278(13):11648-53.
|
REF 34 |
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett. 2005 Oct 24;579(25):5473-80.
|
REF 35 |
Mdm2 is a novel activator of ApoCIII promoter which is antagonized by p53 and SHP inhibition. Biochem Biophys Res Commun. 2012 Jan 13;417(2):744-6.
|
REF 36 |
Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem. 2003 Feb 21;278(8):6363-70.
|
REF 37 |
MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem. 2010 Aug 27;285(35):26908-15.
|
REF 38 |
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006 Oct;26(19):7269-82.
|
REF 39 |
The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005 Jul;8(1):75-87.
|
REF 40 |
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 2004 Apr 16;279(16):16000-6.
|
REF 41 |
Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene. 2002 Jul 4;21(29):4498-507.
|
REF 42 |
HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation. MBio. 2016 Oct 18;7(5). pii: e01528-16.
|